Skip to main content

Company News

  • July 26, 2024

    Paris 2024: National teams choose bioMérieux’s BIOFIRE® PCR solutions to test athletes

    During this summer's Olympic and Paralympic Games in Paris, several committees and national teams, including the Dutch delegation, will be using the BIOFIRE® range of PCR test solutions developed by bioMérieux to detect respiratory and gastrointestinal infections in their athletes.
  • July 02, 2024

    USDA Awards bioMérieux GENE-UP® Pathogenic E. coli (PEC) as Method of Choice for Shiga Toxin-Producing E. coli (STEC) Detection in USDA Food Safety and Inspection Service (USDA-FSIS) Laboratories

    GENE-UP® PEC assay is a real-time PCR-based AOAC validated solution for the meat, produce, and food safety industry.

  • June 10, 2024

    USDA Awards bioMérieux GENE-UP® CAMPYLOBACTER as Method of Choice for Campylobacter Detection in USDA Food Safety and Inspection Service Laboratories

    GENE-UP® CAMPYLOBACTER is a real-time PCR-based solution that delivers results in under an hour and is AOAC validated for a variety of enrichment medias.

  • June 06, 2024

    bioMérieux and AnaBioTec Announce Partnership to Support the Implementation of Rapid Mycoplasma Testing

    In May 2024, bioMérieux entered into a strategic partnership with AnaBioTec, an analytical service provider for pharmaceutical, biopharmaceutical and cell-based drugs, from early to late phases of development. Both companies intend to advance and transform Mycoplasma testing for the biopharmaceutical and Cell & Gene Therapy (CGT) industries, in Europe.
  • June 04, 2024

    A new R&D building in Italy to innovate in combatting Antimicrobial Resistance

    bioMérieux inaugurated its new Rodolphe Mérieux Campus on May 31, in Bagno a Ripoli, Italy, in the presence of Alain Mérieux, Chairman of Institut Mérieux, and Pierre Boulud, Chief Executive Officer of bioMérieux. The site comprises of a new R&D center focusing on the fight against Antimicrobial Resistance. This is the result of an investment of €9 million.